Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease

Judit Mally, Attila B. Kovacs, T. W. Stone

Research output: Contribution to journalArticle

22 Citations (Scopus)


Twenty de novo patients with Parkinson's disease (Hoehn-Yahr stages I, II, III) were studied in a double blind trial after introducing (-)-deprenyl monotherapy. The parkinsonian symptoms were assessed by a novel graded clinical rating scale, by UPDRS and by the North Western self-rating scale. A significant change was observed in motor behaviour and daily activity (UPDRS) after 3 weeks of treatment with (-)-deprenyl at 10 mg/day. The total scores using UPDRS and the North Western ratings were changed significantly after 4 weeks. The greatest changes observed were in walking and in hypokinesia. Rigidity was not modified by (-)-deprenyl.

Original languageEnglish
Pages (from-to)143-145
Number of pages3
JournalJournal of the Neurological Sciences
Issue number1-2
Publication statusPublished - Dec 1995



  • (-)-Deprenyl
  • MAO-B
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this